Compare Amgen, Inc. (AMGN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Xpeng Inc - ADR — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Xpeng Inc - ADR trades at $12.98 (market cap $12.50B). The key difference: Amgen, Inc. is far larger — about 15.7× Xpeng Inc - ADR's market cap, and Amgen, Inc. pays a 2.77% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| AMGN | XPEV | |
|---|---|---|
Market Cap | $196.12B | $12.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $28.07 |
52-Week Low | $271.18 | $12.09 |
Enterprise Value | $241.41B | $14.62B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XPEV trades at $13.03, up 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $73.9B but a net loss of $2.3B, continuing negative profitability trends. Recent news highlights include Robotaxi testing and European market expansion, while analyst consensus remains 64.7% buy despite cash flow challenges.
Outlook is mixed: growth in autonomous driving and international markets offers upside, but persistent losses and competitive pressures pose significant risks. Investors should weigh innovation potential against financial sustainability in the volatile EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
